Abstract: Aspects of the present invention are directed to a method for improving the occlusiveness of a topical pharmaceutical or cosmetic formulation in use in a patient in need thereof, comprising adding to the formulation at least 0.1-to about 10% w/w of one or more of a monofatty acid ester of glycerin and/or one or more of a monofatty acid ester of glycol, or mixtures thereof. Aspects of the present invention are also directed to a method for maintaining skin barrier efficiency of the stratum corneum of a patient in need thereof, comprising applying to the skin of said patient a pharmaceutical or cosmetic formulation containing at least 3% w/w of one or more of a monofatty acid ester of glycerin and/or one or more of a monofatty acid ester of glycol, or mixtures thereof.

Abstract: This document provides methods and materials involved in treating cardiovascular conditions such as calcific aortic valve stenosis. For example, methods and materials for using sGC agonists or a combination of sGC agonists and PDE5A inhibitors to reduce calcification of heart valves and/or vessels or to slow progression of aortic sclerosis to calcific aortic valve stenosis are provided.

Abstract: The present invention relates to: a pharmaceutical composition containing lysophosphatidylcholine or analogs thereof and antibiotics as active ingredients for boosting immunity or the treatment of bacterial infections; a method for boosting immunity or the treatment of bacterial infections, which comprises a step for administering the composition; and a kit containing the composition for boosting immunity or the treatment of bacterial infections.

Abstract: The present invention refers to glycerophosphoinositols (GPIs) and derivatives thereof for use in the treatment of pathologies related to a Lipopolysaccharide (LPS)-activated tissue-factor (TF) activity, as pathologies induced by high bacteremia, i.e. septic shock.

Abstract: The present invention relates to a suspoemulsion comprising the following ingredients (1), (2), (3), (4), (5), and (6): an ingredient (1): low water-soluble liquid pesticidal ingredient, an ingredient (2): low water-soluble pesticidal active ingredient which is solid at normal temperature, an ingredient (3): polyoxyalkylene block copolymer, an ingredient (4): phosphate ester salt and/or sulfate ester salt of polyoxyethylene aryl phenyl ether, an ingredient (5): ligninsulfonic acid salt, and an ingredient (6): water. The suspoemulsion of the present invention is a formulation having excellent storage stability, which suppresses the particle growth of dispersoids of an ingredient (1) and an ingredient (2) during storage at high temperature and low temperature, and causes neither aggregation nor separation of dispersoids, nor formation of a hard cake, nor a change in appearance.

Abstract: The use of therapeutically active lipids for organ/tissue-specific enrichment for the treatment of inflammatory, ischemic or degenerative disorders and/or for stimulating a regeneration is arranged and developed such that the lipids are bound on application to carrier molecules for which cell-specific uptake systems in the cells of the organs and/or tissue exist. In addition, a method of producing organ/tissue-specific therapeutically active lipids for treatment of inflammatory, ischemic or degenerative disorders and/or stimulation of a regeneration, in particular for treating inflammatory liver disorders, is claimed, which is arranged and developed such that lysophosphatidylethanolamine (LysoPE) is coupled to the carboxyl group of ursodeoxycholate (UrsoDOCA) converted to an ester to give a LysoPE-DOCA compound.

Abstract: A method of treating a subject and preventing in a subject age-dependent basal forebrain cholinergic dysfunction related neurodegenerative disorders, comprising: administering a lipid composition comprising a therapeutically effective amount of highly enriched 1-acyl chains/2-docosahexaenoic acid containing molecular species of highly pure phospholipids to promote survival of aged basal forebrain cholinergic neurons, the phospholipids selected from the group consisting of phosphatidylserine, phosphatidylethanolamine, and phosphatidyl-monomethylethanolamine.

Abstract: The present invention provides insecticidal lipids and lipid fractions from fungi of the phylum Ascomycota, together with compositions comprising such lipids and lipid fractions and methods of preparing same. Methods for the biological control of insects, such as phytopathogenic insects, using the lipids and lipid fractions or compositions comprising said lipids optionally together with one or more insecticidal or entomopathogenic agents including entomopathogenic fungi, are also provided.

Abstract: The present invention provides drug-free adaptable aggregate compositions, typically having a form of bilayer vesicles suspended in a polar, optionally thickened, fluid comprising different pharmaceutically acceptable excipients for use in or on a mammal for any medical indication, specifically for non-invasive treatment of local inflammation and the associated pain, in particular for use on the skin and underlying tissues, including muscles and/or superficial joints. Accompanying guidelines for selecting components to thereby optimizing the formulations are also provided.

Abstract: A blend for use in a personal care composition comprises a dialkyl amphiphilic component and an ester of a long chain branched fatty acid and a long chain branched alcohol. The blend can be pastillated and/or flaked, and can be used as the oil phase of an oil-in-water emulsion. The blend can be used in a moisturiser composition for moisturising skin.

Abstract: The novel active compound combinations of a carboxamide of the general formula (I) (group 1) in which R, G, R1 and A have the meanings given in the description and the active compound groups (2) to (23) listed in the description have very good fungicidal properties.

Abstract: The present invention relates to novel methods for selective localization of active agents both at and in mitochondria within living cells, as well as corresponding active agents that penetrate through the cell membrane into the cells without further adjuvants and there can be localized both at and in mitochondria. These active agents are substituted with at least one monohydroxy mononitrophenyl rest or monohydroxy dinitrophenyl rest.

Abstract: Methods and compositions are provided for treating lung diseases, including but not limited to infections and small cell and non-small cell lung cancer, by conjugating a drug of interest to glycerol ethers or glycerol phosphate ethers.

Abstract: The present invention relates to novel active compound combinations comprising, firstly, at least one known compound of the formula (I) in which R1 and A have the meanings given in the description and, secondly, at least one further known active compound from groups (2) to (27) listed in the description, which combinations are highly suitable for controlling animal pests such as insects and unwanted acarids and also phytopathogenic fungi.

Abstract: A penetrating composition can include an active agent that has an activity that is either beneficial for plants or controls pests. The composition can also include a penetrant that is present in an effective amount for carrying the at least one active agent into or through a medium, the medium being at least one of a plant, soil, or pest. Also, penetrating composition can be used for increasing the permeation of an active agent in an animal. The composition includes an active agent having an activity that is beneficial for an animal. Also, the composition includes a penetrant selected from the group consisting of biosurfactants, glycolipids, lipopeptides, favolipids, lipoproteins, phospholipids, lipopolysaccharide-protein complexes, polysaccharide-protein-fatty acid complexes, and combinations thereof. A biosurfactant composition can include an effective amount of a biosurfactant for controlling a pest, preserving a plant cutting, or reducing effects of environmental stress on a plant.

Abstract: The present invention relates to compounds for the inhibition of pyruvate kinase and ATP production which are capable of inhibiting cancer cells proliferation.

Abstract: The present invention provides phospholipid in a crystalline form, a method for its preparation, compositions comprising it and its use in the treatment of damaged tissue.

Abstract: A method of treating a subject and preventing in a subject age-dependent basal forebrain cholinergic dysfunction related neurodegenerative disorders, comprising: administering a lipid composition comprising a therapeutically effective amount of highly enriched 1-acyl chains/2-docosahexaenoic acid containing molecular species of highly pure phospholipids to promote survival of aged basal forebrain cholinergic neurons, the phospholipids selected from the group consisting of phosphatidylserine, phosphatidylethanolamine, and phosphatidyl-monomethylethanolamine.

Abstract: The present invention relates to a new class of compounds having ?? T cells activating properties referred to herein as angelyl or tiglyl phosphoesters, compositions comprising any of these compounds and methods for regulating an immune response in a subject comprising the step of administering these compounds.

Abstract: Novel phospho-derivatives of branched-chain lipophilic molecules useful for permeabilizing biological barriers and for inhibiting tumor growth are disclosed. Pharmaceutical compositions comprising phospho-derivatives of branched-chain lipophilic molecules and their uses are also disclosed.

Abstract: The present invention relates to novel compounds that contain PNA units substituted with phosphonic acid ester functions or phosphonic acid functions, and have at least one chiral center. The compounds may be used for the treatment of viral diseases, such as AIDS.

Abstract: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion.

Abstract: Optionally O-substituted glycero-phosphoinositol derivatives, their analogues and their salts wherein the substitutents: R?1, R?2, R2, R3, R4, R5, R6 have the described meaning, their synthesis and their pharmacological effect as modulators of the activation or over-stimulation of cPLA2.

Abstract: There is provided a method of modifying vasoactivity by regulating a soluble A? pro-inflammatory pathway. Also provided is a method of modifying inflammatory reactions in microglia and neurons by regulating a soluble A? pro-inflammatory pathway. A method of treating patients with vascular disease by modifying an intracellular soluble A? pro-inflammatory pathway is also provided. A pharmaceutical composition consisting essentially of an effective amount of a soluble A? pro-inflammatory pathway regulator in a pharmaceutically effective carrier is also provided.

Abstract: Disclosed are surfactant compounds and compositions that are antimicrobial. Also provided are polymeric compositions incorporating the surfactant compounds. The polymeric compositions may be used to form antibacterial coatings on surfaces.

Abstract: Linoleic acid and related cardiolipin products are used as dietary supplements that provide cardiac benefits against a variety of cardiac related symptoms and diseases. For example, the disclosed compositions and methods may be used to treat or prevent hypertension, ischemic cardiomyopathy, heart disease, Barth Syndrome and heart failure.

Abstract: This invention relates to a kind of Erianin salt and the preparing process thereof. The said Erianin salt is a compound with the following general formula (I), wherein R is the salt formed by monobasic acid radical of inorganic oxacid combining with metals, ammonium salts, organic amine. This invention also relates to a pharmaceutical composition comprising Erianin salt. Compared with Erianin, the said Erianin salt has far better solubility, which can improve the bioavailability and show better antineoplastic efficacy.

Abstract: The present invention relates to a new class of compounds having ?? T cells activating properties referred to herein as angelyl or tiglyl phosphoesters, compositions comprising any of these compounds and methods for regulating an immune response in a subject comprising the step of administering these compounds.

Abstract: The present invention provides compounds that are inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.

Abstract: Benzamidine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an effect of inhibiting activated blood-coagulation factor X, and they are useful as agents for preventing or treating various diseases caused by thrombi or emboli.

Abstract: Methods and compositions for selectively inactivating viruses in biological compositions, including contacting the composition with an organic solvent and an ethyleneimine oligomer inactivating agent, are disclosed.

Abstract: The invention relates to an insecticidal and miticidal composition which contains as active ingredients chlorfenapyr in combination with one or more organophosphoric acid ester-type compounds and to a method for controlling insecticidal or miticidal pests which have acquired resistance to commercial insecticidal and miticidal agents.

Abstract: The invention relates to use of (a) compounds of phosphorus containing at least partly lipophilic organic radicals together with (b) urea and/or urea derivatives in selected quantity ratios of (a) to (b) as a soil additive for biologically controlling plant-parasitic soil nematodes by strengthening the correspondingly antagonistic soil potential, more particularly by strengthening the growth of antagonistic and/or nematicidal rhizosphere bacteria and/or corresponding mycorrhiza strains—and at the same time strengthening the growth of cultivated plants in soil. The multicomponent mixtures which strengthen bacterial growth are preferably introduced into the region of the plant roots in the form of an aqueous preparation using plant-compatible emulsifiers before and/or during plant growth. Components (a) and (b) are used in such quantity ratios that the ratio by weight of C to N is no higher than 6:1 and preferably no higher than 5:1.

Abstract: The object of the invention is to provide a medicament which is suitable for the treatment of tumors, such as via topical administration.

Abstract: The invention relates to a pharmaceutically acceptable prodrug which is a covalent conjugate of a pharmacologically active compound and an intracellular transporting adjuvant, characterized by the presence of a covalent bond which is scission-sensitive to intracellular enzyme activity. The prodrug may be used in a technique for treating a condition or disease in a mammal related to supranormal intracellular enzyme activity, whereby on administering it to a human having such condition or disease, the bond is broken in response to such activity, and the pharmacologically active compound is activated selectively within cells having such supranormal intracellular enzyme activity.

Abstract: Benzamidine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an effect of inhibiting activated blood-coagulation factor X, and they are useful as agents for preventing or treating various diseases caused by thrombi or emboli.

Abstract: Methods and compositions for selectively inactivating viruses in biological compositions, including contacting the composition with an organic solvent and an ethyleneimine oligomer inactivating agent, are disclosed.

Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule incoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.

Abstract: A method and composition for the treatment of HIV infection, HBV infection, or abnormal cellular proliferation in humans and other host animals is disclosed that includes the administration of an effective amount of a 1,3-oxaselenolane nucleoside or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

Abstract: This invention relates to a method of treating patients afflicted with acute renal failure. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.

Abstract: A pharmaceutical formulation for stimulating growth of Gram-positive Bacilli and increasing the acidity in vagina comprises sucrose and/or maltose, optionally with other sugars, viscous base, and anti-fungal and/or anti-bacterial agents.

Abstract: Compositions containing 2-(phosphonomethyl)-pentanedioic acid (PMPA) and pha. and .beta. N-acetyl-aspartyl-glutamate (NAAG) are appropriate means for treatment of neuronal tissue injury that may result from such factors as injury, toxicity, hypoxia or ischemia (a frequent cause of hypoxia). Target tissues include the brain, spinal cord and retina.

Abstract: A method of lubrication of a mammalian joint or other physiological articulation which comprises administering a composition comprising one or more phospholipids in association with propylene glycol.

Abstract: The present invention relates to a dimeric urethane compounds derived from monohydric alcohols, generally fatty alcohols, and a diisocyanate according to the following reaction scheme: ##STR1## wherein R.sub.1 is selected from the group of saturated or halogen substituted linear, cyclic or branch-chained hydrocarbons and R.sub.2 is a linear, cyclic or branch-chained alkyl or aminoalkyl group ranging from two to 200 carbon atoms, preferably two to 50 carbons, more preferably 6 to 36 carbons, said urethane compound being substantially free from terminal hydroxyl groups.

Abstract: A pesticidal composition to noxious organisms which comprises a diarylalkane and an active component effective for killing or repelling noxious organisms and the diarylalkane is at least one member selected from the group consisting of butyl diphenylmethane, butyl-1,1-diphenylethane and butyl-1,2-diphenylethane. The used diarylalkane has a high dissolving power to the effective component, a high boiling point and a high flash point with low unpleasant smell and does not deteriorate the effective component in the pesticidal composition.

Abstract: This invention relates to a method for improving the efficiency of a drug containing a free carboxy group, the improvement comprising esterifying said carboxy group to the hydroxy group of the glycerol portion of a glycerolphospholipid ester having the formula: ##STR1## or pharmaceutically acceptable salts thereof wherein one of R.sub.1 and R.sub.2 is hydrogen and the other is hydrogen, a hydrocarbyl fatty acid acyl group having 4-26 carbon atoms or a hydrocarbyl heteroatom fatty acid acyl group having 3-25 carbon atoms, or ##STR2## and R is a naturally occurring polar head group characteristic of a glycerophospholipid isolated from endogenous sources;R.sub.3 is hydrogen or lower alkyl andR.sub.

Abstract: An external preparation containing DL-.alpha.-tocopherol 2- L-ascorbic phosphoric diester and/or a salt thereof, and at least one ultraviolet absorbing agent. The cross-linking of collagen is suppressed and an excellent cutaneous aging resisting effect is obtained.

Abstract: The invention relates to an inositol phosphate containing pharmaceutical composition which comprises an aliphatic ester or ether for improvement of the bioavailability of the inositol phosphate in mammals including man at non-parenteral administration. The invention also covers the use of at least one aliphatic ester or ether compound for the preparing of an inositol phosphate containing medicament with improved bioavailability of inositol phosphate in mammals including man at non-parenteral administration.

Abstract: The present invention comprises dipropylene glycol dibenzoate and diethylene glycol dibenzoate, the improvement comprising the addition of dipropylene glycol monobenzoate or diethylene glycol monobenzoate, whereby the plasticizer is resistant to fungal growth.

Abstract: The present invention provides compounds that are inducers or inhibitors of apoptosis of apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.